Thoratec (NAS: THOR) reported earnings on Nov. 1. Here are the numbers you need to know.
The 10-second takeaway
For the quarter ended Sep. 29 (Q3), Thoratec beat expectations on revenues and beat expectations on earnings per share.
Compared to the prior-year quarter, revenue grew and GAAP earnings per share grew significantly.
Gross margins dropped, operating margins dropped, net margins expanded.
Thoratec logged revenue of $117.8 million. The 19 analysts polled by S&P Capital IQ wanted to see net sales of $111.7 million on the same basis. GAAP reported sales were 15% higher than the prior-year quarter's $102.6 million.
Source: S&P Capital IQ. Quarterly periods. Dollar amounts in millions. Non-GAAP figures may vary to maintain comparability with estimates.
EPS came in at $0.49. The 17 earnings estimates compiled by S&P Capital IQ averaged $0.39 per share. GAAP EPS of $0.41 for Q3 were 37% higher than the prior-year quarter's $0.30 per share. (The prior-year quarter included -$0.02 per share in earnings from discontinued operations.)
Source: S&P Capital IQ. Quarterly periods. Non-GAAP figures may vary to maintain comparability with estimates.
For the quarter, gross margin was 69.3%, 60 basis points worse than the prior-year quarter. Operating margin was 27.8%, 80 basis points worse than the prior-year quarter. Net margin was 20.6%, 310 basis points better than the prior-year quarter.
Next quarter's average estimate for revenue is $115.4 million. On the bottom line, the average EPS estimate is $0.38.
Next year's average estimate for revenue is $472.1 million. The average EPS estimate is $1.81.
The stock has a four-star rating (out of five) at Motley Fool CAPS, with 154 members out of 174 rating the stock outperform, and 20 members rating it underperform. Among 45 CAPS All-Star picks (recommendations by the highest-ranked CAPS members), 40 give Thoratec a green thumbs-up, and five give it a red thumbs-down.
Of Wall Street recommendations tracked by S&P Capital IQ, the average opinion on Thoratec is outperform, with an average price target of $40.00.
Add Thoratec to My Watchlist.
The article Thoratec Beats on Both Top and Bottom Lines originally appeared on Fool.com.
Seth Jayson had no position in any company mentioned here at the time of publication. You can view his stock holdings here. He is co-advisor ofMotley Fool Hidden Gems, which provides new small-cap ideas every month, backed by a real-money portfolio. The Motley Fool has no positions in the stocks mentioned above. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.